KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Change in Taxes (2021 - 2025)

Historic Change in Taxes for AbCellera Biologics (ABCL) over the last 5 years, with Q3 2025 value amounting to -$12.2 million.

  • AbCellera Biologics' Change in Taxes fell 34281.57% to -$12.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.4 million, marking a year-over-year increase of 3604.62%. This contributed to the annual value of $6.7 million for FY2024, which is 7816.77% down from last year.
  • As of Q3 2025, AbCellera Biologics' Change in Taxes stood at -$12.2 million, which was down 34281.57% from -$3.2 million recorded in Q2 2025.
  • AbCellera Biologics' Change in Taxes' 5-year high stood at $70.0 million during Q1 2022, with a 5-year trough of -$87.2 million in Q3 2022.
  • Its 5-year average for Change in Taxes is -$4.5 million, with a median of -$3.2 million in 2025.
  • Within the past 5 years, the most significant YoY rise in AbCellera Biologics' Change in Taxes was 124265.88% (2022), while the steepest drop was 1146701.43% (2022).
  • Quarter analysis of 5 years shows AbCellera Biologics' Change in Taxes stood at $16.0 million in 2021, then crashed by 434.78% to -$53.7 million in 2022, then soared by 103.31% to $1.8 million in 2023, then surged by 763.41% to $15.4 million in 2024, then plummeted by 179.45% to -$12.2 million in 2025.
  • Its Change in Taxes was -$12.2 million in Q3 2025, compared to -$3.2 million in Q2 2025 and -$4.4 million in Q1 2025.